{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:19:42Z","timestamp":1790972382492,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2006,8,10]],"date-time":"2006-08-10T00:00:00Z","timestamp":1155168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Hodgkin transformation is a rare complication of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). In this study, the authors assessed the incidence, presenting characteristics, and outcomes of patients with CLL\/SLL who developed Hodgkin lymphoma (HL).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>An electronic database search of patients with CLL\/SLL who presented at The University of Texas M. D. Anderson Cancer Center Department of Leukemia between 1975 and 2005 was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Among 4121 patients with CLL\/SLL, 18 patients (0.4%) developed HL. Presenting features included B\u2010symptoms (67%), lymph node enlargement (79%), splenomegaly (43%), hepatomegaly (29%), hypercalcemia (6%), infection (6%), and mental status changes (6%). The median age was 72 years (range, 49\u201381 years), and there was a male preponderance (78%). The median time from CLL to HL diagnosis was 4.6 years (range, 0\u201312.9 years). Fourteen patients (78%) had been previously treated for CLL\/SLL. Ten patients (56%) had received &gt;1 prior therapy. The median \u03b2<jats:sub>2<\/jats:sub>\u2010microglobulin level was 4.5 mg\/L, and the median lactate dehydrogenase level was 610 IU\/L. Epstein\u2013Barr virus (EBV) was positive by in situ hybridization for EBV\u2010encoded RNA in 3 of 4 tested patients. Fourteen patients (78%) received chemotherapy. The overall response rate was 44% (complete response rate, 19%). The median overall survival duration was 0.8 years (range, 0.03 years\u20136.7<jats:sup>+<\/jats:sup> years). The median failure\u2010free survival (FFS) duration was 0.4 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The rates of response, survival, and FFS in patients with Hodgkin transformation of CLL\/SLL were inferior to those reported in patients with de novo HL and were similar to those in patients with Richter syndrome. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.22121","type":"journal-article","created":{"date-parts":[[2006,8,10]],"date-time":"2006-08-10T13:49:36Z","timestamp":1155217776000},"page":"1294-1302","source":"Crossref","is-referenced-by-count":110,"title":["Hodgkin transformation of chronic lymphocytic leukemia"],"prefix":"10.1002","volume":"107","author":[{"given":"Apostolia\u2010Maria","family":"Tsimberidou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick B.","family":"Hagemeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.","family":"Bueso\u2010Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,9]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/93.3.333"},{"key":"e_1_2_6_3_2","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1182\/blood.V91.5.1757","article-title":"Origin of the Hodgkin\/Reed\u2010Sternberg cells in chronic lymphocytic leukemia with \u201cHodgkin's transformation.\u201d","volume":"91","author":"Ohno T","year":"1998","journal-title":"Blood."},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199209000-00004"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199101000-00004"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/99.6.658"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609054836"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/103.4.479"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/99.3.317"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810701)48:1<48::AID-CNCR2820480112>3.0.CO;2-#"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830480220"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.137"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.0187"},{"key":"e_1_2_6_14_2","first-page":"459","volume-title":"Chronic Lymphoid Leukemias","author":"Seymour JF","year":"2001"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392104"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/84.18.1422"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2454"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401389"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004280000214"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1989.tb03039.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000063417"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(02)00004-8"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000123500"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/10245330310001594225"},{"key":"e_1_2_6_25_2","first-page":"878","article-title":"Chronic lymphocytic leukemia and Hodgkin's disease. Clinicopathologic study of three cases with good prognosis","volume":"85","author":"Serratrice De Roux C","year":"2000","journal-title":"Haematologica."},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01744374"},{"key":"e_1_2_6_27_2","first-page":"91","article-title":"Richter's transformation of chronic lymphocytic leukemia with Hodgkin's\u2010like cells is associated with Epstein\u2010Barr virus infection","volume":"7","author":"Rubin D","year":"1994","journal-title":"Mod Pathol."},{"key":"e_1_2_6_28_2","first-page":"3907","article-title":"Implication of the Epstein\u2010Barr virus in the progression of chronic lymphocytic leukaemia\/small lymphocytic lymphoma to Hodgkin\u2010like lymphomas","volume":"17","author":"Petrella T","year":"1997","journal-title":"Anticancer Res."},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200405000-00018"},{"key":"e_1_2_6_30_2","first-page":"282a","article-title":"Increased mortality associated with higher dose cyclophosphamide plus fludarabine in advanced stage indolent lymphoma patients treated on E1496, an ECOG and CALGB study","volume":"21","author":"Hochster H","year":"2002","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022473"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92411-L"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.22121","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.22121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:33:06Z","timestamp":1760268786000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.22121"}},"subtitle":["The M. D. Anderson Cancer Center experience"],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,9,15]]}},"alternative-id":["10.1002\/cncr.22121"],"URL":"https:\/\/doi.org\/10.1002\/cncr.22121","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}